NCT06883006 Regulation of Emotion, Sleep Extension, and mTBI
| NCT ID | NCT06883006 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Merrimack College |
| Condition | Mild Traumatic Brain Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2025-02-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Concussions are incredibly common, and often result in severe and long lasting symptoms, including, but not limited to, sleep deprivation and emotion dysregulation. This study aims to demonstrate the therapeutic benefits of sleep extension (napping) on emotion regulation in individuals after they sustain a concussion. Thus, sleep extension may be a cost-effective, low risk, supplemental treatment for those with emotion dysregulation following a concussion. The main questions it aims to answer are: 1. Is a nap an effective way to improve emotion regulation in individuals with a concussion? 2. Does a nap reduce the required executive resources necessary to regulate emotions in individuals with a concussion?
Eligibility Criteria
Inclusion Criteria: 1. Between the ages of 18 and 35 years old. 2. Have normal or corrected to normal vision 3. Sustained a FIRST or SECOND concussion within the last 2-3 weeks 4. No sleep disorders 5. Is not a shift worker Exclusion Criteria: 1. Under 18 or over 35 years old. 2. Not have corrected normal vision with glasses or contacts 3. Has an astigmatism in both eyes 4. Had a concussion over 3 weeks ago 5. Has sleep disorder 6. Is a shift worker
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06883006 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Mild Traumatic Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06883006 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06883006 currently recruiting?
Yes, NCT06883006 is actively recruiting participants. Contact the research team at kurdziell@merrimack.edu for enrollment information.
Where is the NCT06883006 trial being conducted?
This trial is being conducted at North Andover, United States.
Who is sponsoring the NCT06883006 clinical trial?
NCT06883006 is sponsored by Merrimack College. The trial plans to enroll 60 participants.